Welcome to edition 223 of Insider Weekends. Insider buying decreased last week with insiders buying $30.92 million of stock compared to $49.49 million in the week prior. Selling increased with insiders selling $587.59 million of stock last week compared to $469.15 million in the week prior.

Stocks were able to leverage some optimistic news and dovish words from the Fed to take another stab at an upside breakout attempt last week.

In this weekly update, I give my view of the current market environment, offer a technical analysis of the S&P 500 chart, review our weekly fundamentals-based SectorCast rankings of the ten U.S. business sectors, and then offer up some actionable trading ideas, including a sector rotation strategy

Except for one gas utility fund (GASFX), only Health Care mutual funds outperformed the S&P 500 over multiple long and short periods (including 2008) with “reasonable” volatility for return generated.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) yesterday announced the closing of its acquisition of rights to defibrotide in the United States (U.S.) and all other countries in the Americas from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau).

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter ended June 30, 2014 and updated financial guidance for 2014.